Seven startups walked away with cash prizes from this year's MassChallenge accelerator program in Houston. Photo via Getty Images

MassChallenge named its winners of its 2020 accelerator at a virtual event on October 22. The program awarded a total of $200,000 in equity-free prizes across seven startups from its second Houston cohort.

This year's program took place completely virtually due to the pandemic. Already, the 56 startups involved in the cohort have raised $44.4 million funding, generated $24 million in revenue, and created 297 jobs, says Jon Nordby, managing director of MassChallenge Texas in Houston, in a news release.

"This has been a year full of change, to say the least," he says. "But startups thrive in uncertain times — because they can move fast and remain agile, they are able quickly meet each new need that arises. I'm extremely proud of the startups in our 2020 cohort — during the course of the program, they've pivoted, adjusted, and evolved in order to grow their businesses."

The startups that won across the Houston cohort included Houston-based PATH EX Inc., which won the $100,000 Diamond Award, is focused on the rapid diagnosis and treatment of sepsis through an unique pathogen extraction platform.

Four companies won $25,000 Gold Awards:

  • Healium, based in Columbia, Missouri, is an extended reality device created for self-management of anxiety.
  • Ozark Integrated Circuits Inc., based in Fayetteville, Arkansas, specializes in problem solving using technology and software in the harshest environments – from jet engines to earth orbit.
  • PREEMIEr Diagnostics, based in Southfield, Michigan, created a way to identify which premature infants need an adjustment to their glucose levels to prevent them from losing vision.
  • Scout Inc., based in Alexandria, Virginia, is developing the first commercial in-space satellite inspection service.

Two companies won the Sidecar Awards, securing each a $25,000 Innospark Artificial Intelligence Prize.

  • Articulate Labs, based in Dallas, makes mobile, adaptive devices to help knee osteoarthritis and knee replacement patients rehabilitate on the go during everyday activity.
  • Houston-based Starling Medical has tapped into tech to optimize urinary catheter for patients with neurogenic bladder dysfunction.
The Houston Angel Network awarded Ozark Integrated Circuits their prize of $50,000.
"The progress these entrepreneurs made in just a few months has all of the hope, drama, anticipation, and optimism of seeing dawn break after a particularly difficult night," says Wogbe Ofori, Principal at 360Approach and a MassChallenge mentor, in the release. "It's fulfilling, actually, and makes me proud to be a MassChallenge mentor."
The seven startups were awarded alongside 27 other startups from this year's Austin, Boston, and Rhode Island accelerators at the virtual event. The event was hosted by Chris Denson of Innovation Crush, and featured a fireside chat between Arianna Huffington, founder and CEO of Thrive Global, and Linda Pizzuti Henry, managing director at the Boston Globe.
Earlier this fall, MassChallenge named its 10 startup finalists, whittled down from 56 from 13 countries and 13 states to its first-ever virtual accelerator, which began in June.

"In the face of great uncertainty, MassChallenge Texas in Houston charged forward and did exactly what they ask their startups to do: love the problem," says Houston Mayor Sylvester Turner in the release. "The successful pivot to virtual is a testament to the strength of their global community and the motivation of the Houston ecosystem to get behind new ideas and create businesses that will set roots and grow here.

"As one of the most innovative cities, Houston is a place where startups can thrive – even in the midst of a pandemic. Programs like MassChallenge provide the best practices and networks to ensure startups get the access they need to create sustainable businesses and lasting change."

These are the 10 finalists heading to MassChallenge's virtual awards program next month. Photo courtesy of MassChallenge

MassChallenge Texas names its top 10 companies in its Houston cohort

best of the rest

Boston-based MassChallenge has named its top picks from its second Houston cohort ahead of its awards event. This year's programming, due to the pandemic, was held completely online.

"Great entrepreneurs don't let a crisis go to waste: this cohort was assembled from virtually every industry across 13 different countries and through the twists and turns, their passion became a beacon for the future," says Jon Nordby, managing director of MassChallenge Texas in Houston. "These top startups represent the best qualities of all of us: resilient, ingenious, and able to push ourselves further than we think we are capable. They embody the entrepreneurial spirit that brings hope and progress to society."

The 10 companies — which represent the top 18 percent of the cohort — will now compete in a final round of judging for up to $250,000 in equity-free cash prizes. The winners will be revealed at the 2020 MassChallenge Virtual U.S. Awards, which will be held online.

The 2020 MassChallenge Texas in Houston top 10 finalists are:

  • B2B Pay, based in Helsinki, Finland, is a fintech startup with a multi-bank platform.
  • FloodFrame, based in Richmond just outside of Houston, is a self-deploying flood protection system that can be easily installed to existing houses.
  • Healium, based in Columbia, Missouri, is an extended reality device created for self-management of anxiety.
  • Houston-based Integricote uses nanotechnology research that originated from the University of Houston in the treatment and fortification of materials like wood and concrete.
  • Ozark Integrated Circuits Inc., based in Fayetteville, Arkansas, specializes in problem solving using technology and software in the harshest environments – from jet engines to earth orbit.
  • Houston-based PATH EX Inc. is focused on the rapid diagnosis and treatment of sepsis through a pathogen extraction platform.
  • PREEMIEr Diagnostics, based in Southfield, Michigan, created a way to identify which premature infants need an adjustment to their glucose levels to prevent them from losing vision.
  • Scout Inc., based in Alexandria, Virginia, is developing the first commercial in-space satellite inspection service.
  • Sunnydale, California-based Sizzle is using artificial intelligence to automatically create gaming highlights for the billion gaming viewers.
  • Starling Medical, based in Houston, has tapped into tech to optimize urinary catheter for patients with neurogenic bladder dysfunction.

The 54-company cohort, which is the second based in Houston since the program's launch last year, was challenged early on — much like the other MassChallenge cohorts — to pivot to virtual acceleration over the four-month experience.

Robert Pieroni, director of Economic Development for Central Houston, which was part of the group that worked to bring MCTX to Houston, says he sees a need for this type of accelerator now more than ever.

"MassChallenge's work sources ground-breaking ideas from around the world and invites them into an inclusive village surrounded by a network of tools, resources, and opportunities that help founders accelerate and scale their business to solve humankind's boldest challenges head-on," he says. "The addition of virtual and the rise of distributed teams in response to the pandemic will make it easier for startups to launch and build businesses anywhere."

MassChallenge's Houston cohort will be one of a few featured at the virtual awards event on October 22 at 4 p.m. Headliners for the event include Arianna Huffington, founder and CEO of Thrive Global, and Linda Pizzuti Henry, managing director of the Boston Globe, and Chris Denson of Innovation Crush will be the host. For more information about the event and to register, visit the MassChallenge website.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”